Transmission-reducing and -enhancing monoclonal antibodies against Plasmodium vivax gamete surface protein Pvs48/45
Infection and Immunity · 2024
DOI: 10.1128/iai.00374-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Infection and Immunity, 2024. Verfasst von Geetha P Bansal und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Tropical Medicine, Tulane University, New Orleans, Louisiana, USA. Hauptthemen laut MEDLINE: Malaria, Vivax, Malaria Vaccines. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, HHS | National Institutes of Health.
Abstract (Originalsprache)
Gamete surface protein P48/45 has been shown to be important for male gamete fertility and a strong candidate for the development of a malaria transmission-blocking vaccine (TBV). However, TBV development for Plasmodium vivax homolog Pvs48/45 has been slow because of a number of challenges: availability of conformationally suitable recombinant protein; the lack of an in vivo challenge model; and the inability to produce P. vivax gametocytes in culture to test transmission-blocking activity of antibodies. To support ongoing efforts to develop Pvs48/45 as a potential vaccine candidate, we initiated efforts to develop much needed reagents to move the field forward. We generated monoclonal antibodies (mAbs) directed against Pvs48/45 and characterized putative functional domains in Pvs48/45 using recombinant fragments corresponding to domains D1–D3 and their biological functionality through ex vivo direct membrane feeding assays (DMFAs) using P. vivax parasites from patients in a field setting in Brazil. While some mAbs partially blocked oocyst development in the DMFA, one mAb caused a significant enhancement of the infectivity of gametocytes in the mosquitoes. Individual mAbs exhibiting blocking and enhancing activities recognized non-overlapping epitopes in Pvs48/45. Further characterization of precise epitopes recognized by transmission-reducing and -enhancing antibodies will be crucial to design an effective immunogen with optimum transmission-reducing potential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Tropical Medicine, Tulane University, New Orleans, Louisiana, USA.
- Plataforma de Produção e Infecção de Vetores da Malária, Laboratório de Entomologia - Fiocruz Rondônia, Porto Velho, Rondônia, Brazil.
- Department of Global Health, George Washington University, Washington, DC, USA.
- Programa de Pós-Graduação em Biologia Experimental, Fundação Universidade Federal de Rondônia, Fiocruz Rondônia, Porto Velho, Rondônia, Brazil.
- Yale School of Medicine, New Haven, Connecticut, USA.
ORCID-Profile: Geetha P Bansal, Joseph Vinetz, Nirbhay Kumar
Förderung
- NIAID NIH HHS
- HHS | National Institutes of Health
Zitieren
APA
Bansal, G. P., Araujo, M. S., Cao, Y., Shaffer, E., Araujo, J. E., Medeiros, J. F., Hayashi, C., Vinetz, J., & Kumar, N. (2024). Transmission-reducing and -enhancing monoclonal antibodies against Plasmodium vivax gamete surface protein Pvs48/45. Infection and Immunity. https://doi.org/10.1128/iai.00374-23
Vancouver
Bansal GP, Araujo MS, Cao Y, Shaffer E, Araujo JE, Medeiros JF, et al. Transmission-reducing and -enhancing monoclonal antibodies against Plasmodium vivax gamete surface protein Pvs48/45. Infection and Immunity. 2024. doi:10.1128/iai.00374-23
BibTeX
@article{Bansal2024,
author = {Bansal, Geetha P and Araujo, Maisa da Silva and Cao, Yi and Shaffer, Emily and Araujo, Jessica Evangelista and Medeiros, Jansen Fernandes and Hayashi, Clifford and Vinetz, Joseph and Kumar, Nirbhay},
title = {Transmission-reducing and -enhancing monoclonal antibodies against Plasmodium vivax gamete surface protein Pvs48/45},
journal = {Infection and Immunity},
year = {2024},
doi = {10.1128/iai.00374-23}
}
EUVIMED